Hence, future studies should focus on investigating the underlying neuroprotective mechanism of the TGF-βR1 inhibitors in AD pathogenesis through the blockade of the TGF-β signaling pathway in relation to the NLRP1 inflammasome pathway and Aβ-induced tau hyperphosphorylation. Here, NLRP1 is linked to Alzheimer disease.